Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer (Lilac)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01901146 |
|
Recruitment Status :
Completed
First Posted : July 17, 2013
Results First Posted : August 7, 2019
Last Update Posted : August 7, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer | Drug: ABP 980 Drug: Trastuzumab Drug: Paclitaxel Procedure: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 725 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer |
| Actual Study Start Date : | April 29, 2013 |
| Actual Primary Completion Date : | May 5, 2016 |
| Actual Study Completion Date : | January 27, 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ABP 980
Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase. Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase. |
Drug: ABP 980
ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles. Drug: Paclitaxel Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care). Procedure: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection |
|
Active Comparator: Trastuzumab
Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase. Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase. |
Drug: Trastuzumab
Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Other Name: Herceptin® Drug: Paclitaxel Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care). Procedure: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection |
- Percentage of Participants With a Pathologic Complete Response [ Time Frame: 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase ]
Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue and in axillary lymph nodes, regardless of residual ductal carcinoma in situ (DCIS).
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.
- Percentage of Participants With a Pathologic Complete Response in Breast Tissue Only [ Time Frame: 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase ]
Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue, regardless of residual ductal carcinoma in situ (DCIS).
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.
- Percentage of Participants With a Pathologic Complete Response in Breast Tissue and Axillary Lymph Nodes and Absence of DCIS [ Time Frame: 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase ]
Pathological complete response was defined as the absence of invasive tumor cells in the breast tissue and axillary lymph node(s) and absence of residual DCIS.
Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Females ≥ 18 years of age
- Histologically confirmed invasive breast cancer
- Planning for surgical resection of breast tumor and sentinel node or axillary lymph node resection
- Planning neoadjuvant chemotherapy
- HER2 positive disease
- Measurable disease in the breast after diagnostic biopsy, defined as longest diameter ≥ 2.0 cm
- Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry
- Normal bone marrow function
- Normal hepatic function
- Normal renal function
- Subjects must sign an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form before any study specific procedures
Inclusion Criteria for Randomization:
- Left ventricular ejection fraction (LVEF) of ≥55% by 2D echocardiogram
- Complete all 4 cycles of run-in chemotherapy
Exclusion Criteria:
- Bilateral breast cancer
- Presence of known metastases
- Received prior treatment, including chemotherapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer
- Other concomitant active malignancy or history of malignancy in the past 5 years except treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
- Pre-existing clinically significant (≥ grade 2) peripheral neuropathy
- Any history of documented or current congestive heart failure, current high-risk uncontrolled arrhythmias, current angina pectoris requiring a medicinal product, current clinically significant valvular disease, current evidence of transmural infarction on electrocardiogram (ECG), or current poorly controlled hypertension
- Severe dyspnea at rest requiring supplementary oxygen therapy
- History of positivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV)
- Recent infection requiring a course of systemic anti-infectives that were completed ≤ 14 days before enrollment (with the exception of uncomplicated urinary tract infection)
- Woman of childbearing potential who is pregnant or is breast feeding
- Woman of childbearing potential who is not consenting to use highly effective methods of birth control (eg, true abstinence [periodic abstinence (eg calendar ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception], sterilization, or other non-hormonal forms of contraception) during treatment and for at least 7 months after the last administration of the protocol specified treatment
- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study
- Other investigational procedures while participating in this study are excluded
- Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products, trastuzumab, murine proteins, or to any of the excipients
- Subject previously has enrolled and/or has been randomized in this study
- Subject likely to not be available to complete all protocol required study visits or procedures
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01901146
Show 98 study locations
| Study Director: | MD | Amgen |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Amgen |
| ClinicalTrials.gov Identifier: | NCT01901146 |
| Other Study ID Numbers: |
20120283 2012-004319-29 ( EudraCT Number ) |
| First Posted: | July 17, 2013 Key Record Dates |
| Results First Posted: | August 7, 2019 |
| Last Update Posted: | August 7, 2019 |
| Last Verified: | February 2018 |
|
Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Trastuzumab |
Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological |